Clinical Trials Logo

Stage IIIC Endometrial Carcinoma clinical trials

View clinical trials related to Stage IIIC Endometrial Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT01943058 Withdrawn - Clinical trials for Endometrial Adenocarcinoma

Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer

Start date: March 2014
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well megestrol acetate or levonorgestrel-releasing intrauterine system works in treating patients with atypical endometrial hyperplasia or endometrial cancer. Progesterone can cause the growth of endometrial cancer cells. Hormone therapy using megestrol acetate or levonorgestrel-releasing intrauterine system may fight endometrial cancer by lowering the amount of progesterone the body makes. It is not yet known whether megestrol acetate is more effective than levonorgestrel-releasing intrauterine system in treating atypical endometrial hyperplasia or endometrial cancer.

NCT ID: NCT01764802 Completed - Breast Cancer Clinical Trials

Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer

Start date: October 2010
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well psychosexual intervention works in patients with stage I-III gynecologic or breast cancer. Psychosexual intervention may improve sexual and psychosocial function.

NCT ID: NCT00072176 Completed - Clinical trials for Endometrial Adenocarcinoma

Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer

Start date: May 2004
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well temsirolimus works in treating patients with endometrial cancer that has spread to other parts of the body or has spread from where it started to nearby tissue or lymph nodes and has come back after a period of time during which the cancer could not be detected. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.